Pancreatic Cancer Research

ResearcherYamaguchi UniversityActive in the last 2 years

Taro Takami

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6689-4989; OpenAlex author ID A5085571910, A5123411969. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
25
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 12

  1. A Novel Index Consisting of Age, CA19-9, and Methylated Somatostatin Is Useful for Diagnosing Early Pancreatic Cancer. Co-author DOI 10.1002/cam4.72202↗
  2. High intrapancreatic fat deposition accelerates pancreatic ductal adenocarcinoma growth and metastasis with enrollment of FABP5 upregulation. Last author DOI 10.1038/s41598-026-56838-2↗
  3. Survival Analysis of 4 Different Age Groups of Pancreatic Ductal Adenocarcinoma After Radical Resection From Retrospective Multi-Center Analysis (YPB-003). Co-author DOI 10.1002/cam4.70647↗
  4. [Hemosuccus pancreaticus caused by pancreatic cancer treated with radiation therapy for hemostasis]. Last author DOI 10.11405/nisshoshi.122.130↗
  5. Multicenter Prospective Cohort Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer (YPB-001). Co-author DOI 10.1097/mpa.0000000000002323↗
  6. Correction: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox. Co-author DOI 10.1186/s12885-023-11091-y↗
  7. Retraction Note: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox. Co-author DOI 10.1186/s12885-023-11677-6↗
  8. CA19-9 in Combination with Methylated HOXA1 and SST Is Useful to Diagnose Stage I Pancreatic Cancer. Co-author DOI 10.1159/000527342↗
  9. Combination of CA19-9 and Blood Free-Circulating Methylated RUNX3 May Be Useful to Diagnose Stage I Pancreatic Cancer. Co-author DOI 10.1159/000511940↗
  10. Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox. Co-author DOI 10.1186/s12885-020-07167-8↗
  11. Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo. Co-author DOI 10.18632/oncotarget.25421↗
  12. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo. Co-author DOI 10.1186/s12885-016-2744-9↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shuhei Shinoda · 7 shared papers, 2016–2026 · strength 1.15
  2. Takahiro Yamasaki · 8 shared papers, 2016–2026 · strength 1.09
  3. Hirofumi Harima · 6 shared papers, 2016–2025 · strength 0.89
  4. Isao Sakaida · 7 shared papers, 2016–2023 · strength 0.83
  5. Shigeyuki Suenaga · 4 shared papers, 2021–2026 · strength 0.77
  6. Kaori Hamamoto · 3 shared papers, 2022–2026 · strength 0.66
  7. Shogo Amano · 5 shared papers, 2018–2023 · strength 0.66
  8. Hiroto Matsui Matsui · 4 shared papers, 2021–2025 · strength 0.59
  9. Yutaka Suehiro · 3 shared papers, 2021–2026 · strength 0.48
  10. Hiroaki Nagano · 3 shared papers, 2022–2025 · strength 0.48
  11. Yoshitaro Shindo · 2 shared papers, 2024–2025 · strength 0.37
  12. Tatsuya Ioka · 2 shared papers, 2024–2025 · strength 0.37
  13. Masao Nakajima · 2 shared papers, 2024–2025 · strength 0.37
  14. Hidekazu Tanaka · 2 shared papers, 2024–2025 · strength 0.37
  15. Kimikazu Hamano · 2 shared papers, 2024–2025 · strength 0.37
  16. Shin Hamada · 1 shared paper, 2026 · strength 0.29
  17. Atsushi Masamune · 1 shared paper, 2026 · strength 0.29
  18. Masato Yamamoto · 1 shared paper, 2026 · strength 0.29
  19. Michitaka Kawano · 1 shared paper, 2025 · strength 0.28
  20. Shoko Tabara · 1 shared paper, 2026 · strength 0.26
  21. Yuko Fujimoto · 2 shared papers, 2021–2022 · strength 0.23
  22. Katsuyoshi Ito · 1 shared paper, 2024 · strength 0.17
  23. Keiko Shinjo · 1 shared paper, 2022 · strength 0.12
  24. Yutaka Kondo · 1 shared paper, 2022 · strength 0.12
  25. Hiroaki Nagano · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.